MAYNARD, Mass.--(BUSINESS WIRE)--Allegro Diagnostics, Inc. announced today that Michael D. Webb has been appointed President and Chief Executive Officer, and has also been appointed to the company’s Board of Directors. Mr. Webb has more than 25 years of leadership experience in the biomedical industry, including the diagnostics sector.
“We are delighted to have Mike join Allegro Diagnostics at this exciting time in the company’s development,” stated Andrey Zarur, Chairman of Allegro Diagnostics’ Board of Directors. “We are rapidly advancing through the final phase of development of our first product for the early detection of lung cancer, the BronchoGen™ genomic test. As Allegro prepares for the commercial launch of BronchoGen in the first half of 2012, it is particularly important that Mike brings a record of success in emerging companies, including developing the teams and programs that are necessary for success.”
“Allegro has a compelling and validated technology with the potential to enable the accurate early diagnosis of lung cancer, fulfilling a significant clinical need while also addressing a large market,” said Mr. Webb. “I look forward to leading a company with a very strong scientific foundation, two near-term product opportunities and a productive technology platform that can support the development of future products in the field of lung disease.”
Mr. Webb joins Allegro Diagnostics after previously serving as the founder, President and CEO of Anchor Therapeutics, Inc. Prior to Anchor Therapeutics, Mr. Webb served as President and CEO of EPIX Pharmaceuticals, guiding the company to a leadership position in pharmaceuticals for diagnostic imaging. Mr. Webb is also the Executive Chairman of Virtify, Inc. and has served as Chairman of the Massachusetts Biotechnology Council. Mr. Webb holds an MBA from Northwestern University, a Masters in International Relations from Sussex University and a BA/BS in Biochemistry and Economics from the University of Kansas.
About Allegro Diagnostics
Allegro Diagnostics is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests for the diagnosis, staging and informed treatment of lung cancer and other lung diseases. Allegro has developed a molecular testing platform that utilizes a genomic biomarker to detect early signs of lung cancer in current and former smokers. The company’s lead product is the BronchoGen™ genomic test for use in combination with standard bronchoscopy for the early diagnosis of lung cancer.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6760368&lang=en